Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia

Erstveröffentlichung
2017
Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors
Seymour, John F.
Döhner, Hartmut
Minden, Mark D.
Stone, Richard
Gambini, Dominique
et al.
Institutions
UKU. Klinik für Innere Medizin III
Published in
Leukemia & Lymphoma ; 58 (2017), 6. - S. 1412-1423. - ISSN 1042-8194. - eISSN 1029-2403
Link to publication
https://dx.doi.org/10.1080/10428194.2016.1243680
Funding information
Celgene Corporation
Keywords
Azacitidine; hospitalization; treatment-emergent adverse event; AE; TEAE; risk myelodysplastic syndromes; dna methyltransferase inhibitors; quality-of-life; management; adults; 5-azacytidine; mortality; diagnosis; cells; time
Dewey Decimal Group
DDC 610 / Medicine & health
Metadata
Show full item record